Abstract This Focus Review describes the evolution of artificial proteases, which are synthetic catalysts for peptide hydrolysis that mimic the action of natural proteases. The evolution took place through discovery of catalytic centers for peptide hydrolysis, attachment of substrate‐recognition sites to the catalytic centers, and the advent of target‐selective artificial proteases. Application of the target‐selective artificial proteases led to a therapeutic option for amyloid diseases, such as Alzheimer’s disease and diabetes.